Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and Midostaurin for FLT3 Mutated AML
NCT04982354Phase 2Withdrawn
- Start
- Jul 2022
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML). Primary endpoints: Complete Remission Rate at 24 months, Progression Free Survival at 24 months and 1 more. Planned start Jul 2022; status: withdrawn.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04982354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982354.